Frédéric Lambert

Frédéric Lambert

Auto-generated profile, based on publicly available information

Frédéric Lambert

Center for Human Genetics and Department of Laboratory Medicine University Hospital of Liège Liège Belgium

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
RCRebekah Lee Isla Crake
Rebekah Lee Isla Crake
IGImène Gasmi
Imène Gasmi
JDJordan Dehaye
Jordan Dehaye
FLFanny Lardinois
Fanny Lardinois
RPRaphaël Peiffer
Raphaël Peiffer
ABAkeila Bellahcène
Akeila Bellahcène
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis. Gemcitabine is the first-line therapy for PDAC, but gemcitabine resistance is a major impediment to achieving satisfactory clinical outcomes. This study investigated whether methylglyoxal (MG), an oncometabolite spontaneously formed as a by-product of glycolysis, notably favors PDAC resistance to gemcitabine. We observed that human PDAC tumors expressing elevated levels of glycolytic enzymes together with high levels of glyoxalase 1 (GLO1), the major MG-detoxifying enzyme, present with a poor prognosis. Next, we showed that glycolysis and subsequent MG stress are triggered in PDAC cells rendered resistant to gemcitabine when compared with parental cells. In fact, acquired resistance, following short and long-term gemcitabine challenges, correlated with the upregulation of GLUT1, LDHA, GLO1, and the accumulation of MG protein adducts. We showed that MG-mediated activation of heat shock response is, at least in part, the molecular mechanism underlying survival in gemcitabine-treated PDAC cells. This novel adverse effect of gemcitabine, i.e., induction of MG stress and HSR activation, is efficiently reversed using potent MG scavengers such as metformin and aminoguanidine. We propose that the MG blockade could be exploited to resensitize resistant PDAC tumors and to improve patient outcomes using gemcitabine therapy.

20 November 2013 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
LRLaurence Rozen
Laurence Rozen
SHSophie Huybrechts
Sophie Huybrechts
LDLaurence Dedeken
Laurence Dedeken
CHCatherine Heijmans
Catherine Heijmans
BDBarbara Dessars
Barbara Dessars
ADAnne claire Demulder
Anne claire Demulder

5 November 2020 in Blood
Verified
Journal Article
Open access
JBJudith M. Boer
Judith M. Boer
MVMaria Grazia Valsecchi
Maria Grazia Valsecchi
FHFemke M. Hormann
Femke M. Hormann
ŽAŽeljko Antić
Željko Antić
MZMarketa Zaliova
Marketa Zaliova
RPRob Pieters
Rob Pieters
Background and Aims A novel genetic subtype of B cell precursor acute lymphoblastic leukemia (B-ALL) is characterized by rearrangement of NUTM1 (NUTM1r) on 15q14 resulting in fusion of NUTM1 to one of several partner genes such as CUX1, ACIN1, BRD9, and IKZF1. The downstream effects of NUTM1r include upregulation of the proto-oncogene BMI1 and specific fusions also induce transcription of the HOXA gene cluster (Hormann et al. Haematologica 2019; Li et al. PNAS 2018). This novel subtype is rare in children, but appears to be more prevalent among infants negative for KMT2A rearrangement (KMT2Ar) based on the frequency of karyotypic 15q aberrations (De Lorenzo et al. Leukemia 2014). This international collaborative study aimed to determine the frequency of NUTM1r in infant and pediatric cohorts, and to characterize the demographic, clinical and molecular features of NUTM1r-positive B-ALL. Patients and Methods Interfant-related study groups provided NUTM1 screening results for KMT2Ar-negative Interfant-99 and -06 cases with karyotypic 15q aberration, normal karyotype, or missing karyotype. Additionally, NUTM1r-positive cases of any age were collected from the study groups united in the Ponte di Legno consortium. The identified NUTM1r-positive children were diagnosed between 1995-2019, infants (≤365 days of age) included in the Interfant-99 or 06 trials were diagnosed between 2000-2016, and remaining infants between 1986-2019. The techniques used for the detection of NUTM1r were break-apart FISH, RNA sequencing, and RT-PCR. Event-free survival (EFS) and overall survival (OS) were estimated according to Kaplan-Meier, standard error according to Greenwood, and the curves were compared by log-rank test. Results We identified 81 NUTM1r cases, including 35 Interfant-enrolled infants, 10 other infants and 36 children. NUTM1r was reported to be rare among pediatric B-ALL with an estimated frequency range of 0.28-0.86%. The median age among NUTM1r-positive children was 4.5 years (range 1-15). Among KMT2Ar-negative infants the frequency of NUTM1r was 21.7%. Of NUTM1r-positive infants, 54% were <6 months at diagnosis (median 5.6, range 0.4-11.0 months) compared with 16% in the remaining KMT2Ar-negative infants (median 9.3, range 0.1-11.9; p<0.0001). Other baseline characteristics (WBC, gender, prednisone poor response) were similar between NUTM1r-positive and -negative infants. Of the NUTM1r-positive cases, all achieved complete remission, 82% had minimal residual disease <10e-4 at the end of induction, and no patient received stem cell transplant in first remission. The 4-year EFS was 100% in Interfant-enrolled NUTM1r-positive patients versus 74% (95% CI 65.1-81.0, p=0.001) in the remaining KMT2Ar-negative cases (n=126). The better outcome was confirmed also after adjusting for WBC, gender and prednisone response (p=0.0001). The 4-year OS were 100% and 88.0% (95% CI 80.5-92.7) for NUTM1r-positive and other KMT2Ar-negative infant cases, respectively (p-value=0.04). Children and non-Interfant-enrolled infants treated on different treatment protocols showed 89.4% (95% CI 78.6-1) 4-year EFS and 100% 4-year OS. In order of frequency, NUTM1 fusion partners were ACIN1 (30.4%), CUX1 (21.7%), BRD9 (17.4%), ZNF618 (13%), AFF1 (4.3%), SLC12A6 (4.3%), IKZF1 (2.9%), and three novel partners: ATAD5 (2.9%), CHD4 (1.4%) and RUNX1 (1.4%). Infants mainly showed fusions with ACIN1, CUX1, BRD9 and AFF1, associated with HOXA9 upregulation. Older infants and children showed both HOXA-upregulating and non-HOXA-upregulating fusions. Epigenetic profiling showed a distinct pattern of DNA methylation and histone modification of the HOXA gene cluster region in leukemic cells of an ACIN1-NUTM1 pediatric case compared with KMT2Ar-positive and KMT2Ar/NUTM1r-negative pediatric cases. Conclusions NUTM1r ALL was identified as the second largest subtype in infants, found in 21.7% of KMT2Ar-negative infant B-ALL, representing 5-7% of total infant ALL, and associated with excellent outcome on Interfant standard risk protocols. The favorable outcome was confirmed in the Ponte di Legno cohort of infant and pediatric NUTM1r-positive patients enrolled on different treatment protocols over more than two decades. We conclude that NUTM1r ALL is a favorable genetic subtype in infants and children and possibly eligible for treatment reduction.

4 August 2026 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
FLFrédéric Lambert
Frédéric Lambert
BKBenjamin Koopmansch
Benjamin Koopmansch
RCRafael Fernandez Carazo
Rafael Fernandez Carazo
EDElisa Dardenne
Elisa Dardenne
AKAurore Keutgens
Aurore Keutgens
GVGaëlle Vertenoeil
Gaëlle Vertenoeil

28 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FLFrederic Claude Lambert
Frederic Claude Lambert
RCRafael Fernandez Carazo
Rafael Fernandez Carazo
CLCéline Lété
Céline Lété
NCNicolas Catarin
Nicolas Catarin
EDElisa Dardenne
Elisa Dardenne
AVAdrien DE VOEGHT
Adrien DE VOEGHT
Background: Rare JAK2 fusion rearrangements define an uncommon group of kinase-driven hematologic malignancies whose structural complexity may obscure the biologically relevant expressed fusion. Case presentation: We report a 37-year-old man with cervical/epidural myeloid sarcoma in the setting of acute myeloid leukemia, initially inaspirable bone marrow, and 2.2% circulating blasts. Conventional cytogenetics on leukemic peripheral blood identified a hyperdiploid clone with trisomy 8, aberrant chromosomes 9 and 22, and a derivative chromosome 19 suggestive of a TCF3 rearrangement. Review reclassified material initially suspected to represent additional chromosome 21 copies as two derivative chromosomes 9. Fluorescence in situ hybridization showed JAK2 and TCF3 break-apart abnormalities in 9% and 20% of nuclei, respectively. Optical genome mapping, performed in a pre-routine validation setting, supported a complex rearrangement involving the JAK2 and BCR loci, whereas targeted RNA sequencing identified the expressed BCR::JAK2 transcript, joining BCR exon 1 to JAK2 exon 17. Neither technique characterized the TCF3 abnormality. Formalin-fixed paraffin-embedded tumor profiling revealed a complex copy-number profile, including partial JAK2 gain. Following an early relapse after first consolidation, salvage treatment combining radiotherapy, venetoclax, cytarabine, and ruxolitinib achieved a second complete remission, allowing allogeneic stem cell transplantation. At 1 year, the patient remained in remission with no molecular or cytogenetic evidence of the diagnostic abnormality and full donor chimerism. Conclusions: This integrated approach resolved a cryptic driver rearrangement, established the structure of the expressed BCR::JAK2 transcript, and enabled transcript-informed molecular follow-up. Detection of BCR::JAK2 provided a molecular rationale for incorporating JAK2- directed therapy into the multimodal salvage regimen.

31 August 2026 in Oncogenesis
Verified
Journal Article
Open access
PDF file
PAPierre Adam
Pierre Adam
CSCatherine Salée
Catherine Salée
PBPauline Bomboire
Pauline Bomboire
MSMarty Stepniak
Marty Stepniak
ALArnaud Lavergne
Arnaud Lavergne
MMMarie-Alice Meuwis
Marie-Alice Meuwis
Na⁺-K⁺-2Cl − cotransporter 1 (encoded by SLC12A2 ) is a solute carrier overexpressed in colorectal cancer (CRC), but its functional role remains unclear. Here, we identify NKCC1 as a marker of normal intestinal stem cells, supported by its crypt-base localization, single-cell transcriptomics, and patient-derived organoids, while analyses of public colorectal cancer single-cell datasets further link NKCC1 expression to cancer stem cell populations. Surprisingly, analysis of CRC patient datasets revealed that tumors with lower SLC12A2 expression were associated with poorer relapse-free survival. By stably knocking down NKCC1 in cell lines and organoids, we demonstrate enhanced expression of stemness markers, altered oxidative stress pathways, and increased radioresistance. In contrast, pharmacological inhibition with bumetanide activates AKT/mTORC1 signaling, elevates reactive oxygen species (ROS), and sensitizes cells to oxidative stress. Together, these results highlight NKCC1 as a dual regulator of stemness and redox homeostasis, supporting its role as a potential key player in colorectal carcinogenesis.